Almirall has announced the launch of Nano4Derm, a research project in collaboration with the Institute of Materials Science of Barcelona (ICMAB-CSIC) and the Leitat Technological Centre, which focuses on nanomedicine applied to the treatment of skin diseases. Within the framework of this research project, new innovative formulations will be developed with nano-encapsulated active ingredients for the topical treatment of inflammatory skin diseases, such as acne and psoriasis.
This agreement will enable the development of two types of nanocapsules which contain active ingredients to address current unmet needs and challenges -such as antimicrobial resistance- and provide improved topical treatments in terms of side effects, instability of the active ingredients and absorption by the skin.
Both Almirall and Leitat are members of CataloniaBio. The latter is represented on the Board of Directors by Francesc Mitjans, as Biomed Division Manager.
Peter Guenter, new CEO
In addition, this week Almirall announced that it would be bringing in a new CEO as from 1 October. Belgian Peter Guenter is to replace Eduardo Sanchiz, who a year ago expressed his wish to dedicate more time to his family and to other interests. Guenter has worked with Sanofi over the past 22 years, recently in the post of Executive Vice President of the Diabetes and Cardiovascular global business unit.
Comments